{"filing":{"accession_number":"0001213900-26-078781","cik":"0001788028","ticker":"JSPRW","company_name":"Jasper Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"ea0298316-8k_jasper.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026078781/ea0298316-8k_jasper.htm"},"events":[{"id":18499,"run_id":16629,"accession_number":"0001213900-26-078781","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses completion of a material acquisition of Kira Pharmaceuticals by Jasper Therapeutics in an all-stock transaction, combined with a concurrent $132 million private placement financing. The press release explicitly states \"Jasper has completed the acquisition of Kira Pharmaceuticals\" and describes a consolidated pipeline, management structure, and significant ownership dilution (Jasper pre-acquisition shareholders will own ~6.68% post-transaction). This is a transformative M\u0026A event material to investors.","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17327,"accession_number":"0001213900-26-078781","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses completion of a material acquisition of Kira Pharmaceuticals by Jasper Therapeutics in an all-stock transaction, combined with a concurrent $132 million private placement financing. The press release explicitly states \"Jasper has completed the acquisition of Kira Pharmaceuticals\" and describes a consolidated pipeline, management structure, and significant ownership dilution (Jasper pre-acquisition shareholders will own ~6.68% post-transaction). This is a transformative M\u0026A event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T21:16:42.370379+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17327,"accession_number":"0001213900-26-078781","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses completion of a material acquisition of Kira Pharmaceuticals by Jasper Therapeutics in an all-stock transaction, combined with a concurrent $132 million private placement financing. The press release explicitly states \"Jasper has completed the acquisition of Kira Pharmaceuticals\" and describes a consolidated pipeline, management structure, and significant ownership dilution (Jasper pre-acquisition shareholders will own ~6.68% post-transaction). This is a transformative M\u0026A event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T21:16:42.370379+00:00","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-07-16"}]}